IN2014MN01944A - - Google Patents
Info
- Publication number
- IN2014MN01944A IN2014MN01944A IN1944MUN2014A IN2014MN01944A IN 2014MN01944 A IN2014MN01944 A IN 2014MN01944A IN 1944MUN2014 A IN1944MUN2014 A IN 1944MUN2014A IN 2014MN01944 A IN2014MN01944 A IN 2014MN01944A
- Authority
- IN
- India
- Prior art keywords
- compounds
- combinations
- cell death
- induction
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607103P | 2012-03-06 | 2012-03-06 | |
| PCT/US2013/029391 WO2013134398A1 (en) | 2012-03-06 | 2013-03-06 | Procaspase combination therapy for glioblastoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01944A true IN2014MN01944A (ko) | 2015-07-10 |
Family
ID=49117298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1944MUN2014 IN2014MN01944A (ko) | 2012-03-06 | 2013-03-06 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US9421202B2 (ko) |
| EP (2) | EP2822546B1 (ko) |
| JP (2) | JP6222608B2 (ko) |
| KR (1) | KR102075811B1 (ko) |
| CN (1) | CN104540501B (ko) |
| AU (1) | AU2013230985B2 (ko) |
| BR (1) | BR112014022123B1 (ko) |
| CA (1) | CA2866020C (ko) |
| DK (2) | DK2822546T3 (ko) |
| ES (2) | ES2738448T3 (ko) |
| HK (1) | HK1204985A1 (ko) |
| IN (1) | IN2014MN01944A (ko) |
| MX (1) | MX359209B (ko) |
| RU (1) | RU2636234C2 (ko) |
| WO (1) | WO2013134398A1 (ko) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008134474A2 (en) * | 2007-04-27 | 2008-11-06 | The Board Of Trustees Of The University Of Illinois | Compositions and methods including cell death inducers and procaspase activation |
| CN117257802A (zh) * | 2015-06-05 | 2023-12-22 | 伊利诺伊大学董事会 | Pac-1联合疗法 |
| KR101712638B1 (ko) | 2015-08-19 | 2017-03-07 | 한국과학기술연구원 | Pac-1을 이용한 단백질 발현 조절 시스템과 방법 및 pac-1을 유효성분 포함하는 독시사이클린 길항제 |
| WO2019099873A1 (en) | 2017-11-17 | 2019-05-23 | The Board Of Trustees Of The University Of Illinois | Cancer therapy by degrading dual mek signaling |
| CN113473996B (zh) * | 2019-03-05 | 2024-05-24 | 陶氏环球技术有限责任公司 | 诱导胱天蛋白酶活性 |
| KR20220016104A (ko) * | 2019-05-30 | 2022-02-08 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 암 치료를 위한 프로카스파아제-3 활성화 및 면역요법 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260291A (en) | 1981-08-24 | 1993-11-09 | Cancer Research Campaign Technology Limited | Tetrazine derivatives |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US6403765B1 (en) | 1998-06-16 | 2002-06-11 | Thomas Jefferson University | Truncated Apaf-1 and methods of use thereof |
| EP1100932A2 (en) | 1998-07-27 | 2001-05-23 | PHARMACIA & UPJOHN COMPANY | Method for autoactivation of procaspase 8 |
| US6110691A (en) | 2000-01-06 | 2000-08-29 | Board Of Regents, The University Of Texas System | Activators of caspases |
| US6608026B1 (en) | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
| AU2002241508A1 (en) | 2000-11-20 | 2002-06-24 | Lawrence C. Fritz | Membrane derived caspase-3, compositions comprising the same and methods of use therefor |
| US6878743B2 (en) | 2001-09-18 | 2005-04-12 | Sunesis Pharmaceuticals, Inc. | Small molecule inhibitors of caspases |
| US20040180828A1 (en) | 2003-01-30 | 2004-09-16 | Yigong Shi | Caspase-9 : BIR domain of XIAP complexes and methods of use |
| US7632972B2 (en) | 2003-10-30 | 2009-12-15 | The Board Of Trustees Of The University Of Illionis | Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells |
| US8440610B2 (en) * | 2004-11-12 | 2013-05-14 | Massachusetts Institute Of Technology | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells |
| CN101184491A (zh) * | 2005-05-26 | 2008-05-21 | 伊利诺伊大学评议会 | 包括活化半胱天冬酶-3酶原的癌细胞内选择性细胞凋亡诱导 |
| WO2008134474A2 (en) | 2007-04-27 | 2008-11-06 | The Board Of Trustees Of The University Of Illinois | Compositions and methods including cell death inducers and procaspase activation |
| US20070049602A1 (en) * | 2005-05-26 | 2007-03-01 | The Board Of Trustees Of The University Of Illinois | Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3 |
| ATE524445T1 (de) * | 2005-06-23 | 2011-09-15 | Merck Sharp & Dohme | Benzocycloheptapyridine als inhibitoren der tyrosinkinase met |
| TWI373473B (en) | 2005-09-02 | 2012-10-01 | Otsuka Pharma Co Ltd | Anticancer agent |
| CA2622867A1 (en) * | 2005-09-16 | 2007-03-22 | Schering Corporation | Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor |
| US20070111936A1 (en) * | 2005-11-15 | 2007-05-17 | Vladimir Pak | Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer |
| US7886969B2 (en) | 2005-12-06 | 2011-02-15 | Visa U.S.A. Inc. | Method and system for loading and reloading portable consumer devices |
| DE07797600T1 (de) | 2006-05-19 | 2009-08-13 | The Board Of Trustees Of The University Of Illinois, Urbana | Phosphorhaltige verbindungen mit triphenylmethylphosphonatestern zur behandlung von melanomen oder anderen tumoren |
| RU2360692C1 (ru) | 2007-12-21 | 2009-07-10 | Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) | Средство, стимулирующее апоптоз клеток лейкемии человека |
| AU2009203977A1 (en) | 2008-01-11 | 2009-07-16 | The Regents Of The University Of California | Activators of executioner procaspases 3, 6 and 7 |
| US20100291214A1 (en) | 2008-12-23 | 2010-11-18 | Armark Authentication Technologies, Llc | Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure |
| WO2010091382A1 (en) | 2009-02-09 | 2010-08-12 | The Board Of Trustees Of The University Of Illinois | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs |
| TWI386203B (zh) * | 2011-01-07 | 2013-02-21 | Univ China Medical | 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用 |
| WO2012118978A1 (en) * | 2011-03-03 | 2012-09-07 | The Regents Of The University Of Colorado, A Body Corporate | Methods for treating oncovirus positive cancers |
-
2013
- 2013-03-06 EP EP13758061.9A patent/EP2822546B1/en active Active
- 2013-03-06 BR BR112014022123-5A patent/BR112014022123B1/pt active IP Right Grant
- 2013-03-06 RU RU2014139955A patent/RU2636234C2/ru active
- 2013-03-06 CN CN201380023777.3A patent/CN104540501B/zh active Active
- 2013-03-06 DK DK13758061.9T patent/DK2822546T3/en active
- 2013-03-06 MX MX2014010714A patent/MX359209B/es active IP Right Grant
- 2013-03-06 DK DK17180400.8T patent/DK3290035T3/da active
- 2013-03-06 EP EP17180400.8A patent/EP3290035B1/en active Active
- 2013-03-06 IN IN1944MUN2014 patent/IN2014MN01944A/en unknown
- 2013-03-06 ES ES17180400T patent/ES2738448T3/es active Active
- 2013-03-06 CA CA2866020A patent/CA2866020C/en active Active
- 2013-03-06 AU AU2013230985A patent/AU2013230985B2/en active Active
- 2013-03-06 WO PCT/US2013/029391 patent/WO2013134398A1/en active Application Filing
- 2013-03-06 US US14/383,460 patent/US9421202B2/en active Active
- 2013-03-06 KR KR1020147027850A patent/KR102075811B1/ko active IP Right Grant
- 2013-03-06 JP JP2014561081A patent/JP6222608B2/ja active Active
- 2013-03-06 ES ES13758061.9T patent/ES2646008T3/es active Active
-
2015
- 2015-06-19 HK HK15105885.0A patent/HK1204985A1/xx unknown
-
2016
- 2016-08-22 US US15/243,860 patent/US10085978B2/en active Active
-
2017
- 2017-09-27 JP JP2017186650A patent/JP2018052932A/ja active Pending
-
2018
- 2018-10-01 US US16/148,344 patent/US10874666B2/en active Active
-
2020
- 2020-12-22 US US17/130,387 patent/US11844798B2/en active Active
-
2023
- 2023-11-21 US US18/516,174 patent/US20240082241A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01945A (ko) | ||
| PH12016501139A1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| MX366804B (es) | Translocaciones de la r-espondina y sus metodos de uso. | |
| MX2021001878A (es) | Metodos y composiciones para mejorar las celulas t reguladoras cd4+. | |
| EP2904106A4 (en) | COMPOSITIONS AND METHODS FOR TARGETING STROMAL CELLS FOR THE TREATMENT OF CANCER | |
| MX2016007801A (es) | Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa. | |
| MX2015006478A (es) | Inhibidores de glutaminasa y metodos de empleo. | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| MX360404B (es) | Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr. | |
| GB201106750D0 (en) | Novel compounds | |
| NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| MX356525B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
| PH12018502570A1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
| EP2844736A4 (en) | Modified bacteria and uses thereof for the treatment of carcinomas or tumors | |
| IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| IL239007B (en) | Eribulin for use in the treatment of breast cancer | |
| MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
| MX364002B (es) | Compuestos y composiciones activadoras de enzima. | |
| IN2014MN01944A (ko) | ||
| MX2017015532A (es) | Terapia de combinacion pac-1. | |
| WO2013131089A3 (en) | Potent anticancer activity via dual compound activation | |
| MX2014012535A (es) | Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos. | |
| GB2528604A (en) | Modulation of asymmetric proliferation | |
| MX350868B (es) | Medicamentos y metodos para tratar cancer. |